Ginkgo Bioworks director Christian O. Henry sells $35,405 in shares
At a glance
- $DNA today+1.53%last $8.63
- Vs industry peers+2.41 pts6-peer median −0.88% · far ahead
- Since Nov 15−10.8%from the first trade after the story
- 52-week range60.7% above low$5.37 – $18.22
- Cash runway~6 mo$84.5M cash ÷ $13.3M/mo burn · 10-Q
- In the headline$35,405Amount
Nothing reported about ginkgo bioworks across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Christian O. Henry's $35,405 share sale is a concrete detail—track it against recent patterns before assuming it signals a shift.
- How the stock is trading: $DNA +1.53% in the latest session.
- Timing: It was published over the weekend. The change shown is Friday's, and Monday is the first session that could react. Market holidays are not detected.
Where the stock stands
Ginkgo Bioworks ($DNA) rose 1.53% to $8.63 in the latest session. Over the past month it is down 17.4%. That leaves it 53% below its 52-week high of $18.22 and 61% above its low of $5.37. It has been a volatile year: the high was 3.4 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 9, 2026), $DNA lost $41.0M over the quarter to Sep 30, 2026 on revenue of $27.7M (+37.5% QoQ). Operations used $119.3M of cash over the nine months to Sep 30, 2026 — about $13.3M a month — against $84.5M in cash on Sep 30, 2026. At that pace the cash covers about 6 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $551.8M against $84.5M of cash on Sep 30, 2026. Its most recent filings before this story: 10-Q on Nov 9, 2026, 8-K on Nov 5, 2026, 8-K on Oct 29, 2026. Figures are as filed with the SEC; the $DNA page has the full statements.
How much coverage it is getting
This is the only story on Ginkgo Bioworks in Wook's last 30 days of coverage, so there is no recent run to compare it with.
The bigger picture
In healthcare, news often hinges on regulatory decisions, trial results, and pricing changes—each can tilt a drugmaker’s fate or shift the entire sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
Check $DNA’s SEC filings for direct insights. Wook AI can help compare its current price to past highs or analyze how this week’s coverage stacks up against previous reports.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 15, 2026. $DNA has moved -10.75% ($9.67 to $8.63). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
